Company news - Shenzhen Efung Investment Management Co. Ltd.

Company news

Efung News | Real Biotechnology's Non-Camptothecin Toxin Debuts at CBI 2026, Breaking Through the ADC Drug Resistance Bottleneck

Recently, the CBI 2026 Biomedical Innovation Expo concluded in Suzhou, with an exhibition area of over 36,000 square meters and more than 20,000 participants gathered on site to jointly create a new industry ecosystem. The conference featured multiple parallel forums. At the ADC New Drug Discovery and Front-End Technology Innovation Forum, Dr. Dang Qun, President of Real Biotechnology, shared the companys latest achievements in overcoming ADC drug resistance with its novel non-camptothecin TOPO1 inhibitor platform.ImagePrecision therapeutic approaches represented by next-generation ADC drugs are reshaping the landscape of tumor treatment, among which TOPO1 inhibitor payloads are the most widely used clinically. However, with the widespread use of such drugs, issues of TOPO1 toxin-related target mutations and efflux pump resistance have become increasingly prominent, with cross-resistance emerging among different antibody ADCs, becoming a key bottleneck constraining efficacy improvement...

2026 - 09 - 10
Efung Knowledge Planet | 2026 National Medical Insurance Negotiations in Progress: Collectively Competing for the Medical Insurance "Admission Ticket"

The 2026 National Medical Insurance Drug Catalog Adjustmentachieves full-process parallelism with the Commercial Insurance Innovative Drug Catalog for the first time,opening up a more strategically flexible"walking on two legs" pathway.This article is approximately 2,989 words, with a reading time of about 3 minutes.On the morning of September 8, the three-and-a-half-day on-site negotiation for the National Basic Medical Insurance Catalog officially concluded. On September 9, price negotiation for the Commercial Health Insurance Innovative Drug Catalog officially launched, with final results expected to be announced in late November.Just one day before the negotiations began, the State Council Information Office held a press conference in the "Starting the 15th Five-Year Plan" series, at which Li Tao, Deputy Director and Spokesperson of the National Healthcare Security Administration, introduced arrangements related to medical insurance reform and development, pharm...

2026 - 09 - 09
Efung Hornor | Efung Capital Named to FOFWEEKLY's 2026 Investment Institution Soft Power Ranking – H

Today, FOFWEEKLY officially released its 2026 Investment Institution Soft Power Ranking, and Efung Capital was honored with the Healthcare TOP30 award.In 2026, the equity investment industry finds itself at a critical intersection of "divergence" and "reconstruction." The market has moved past the initial phase of structural recovery and has formally entered a new cycle where legacy holdings coexist with the pursuit of new growth opportunities. Driven by sustained policy guidance and the commercial deployment of hard technologies, the global competitiveness of Chinese enterprises is shifting from "technological breakthroughs" to the validation of "complete business models." As global competition in the tech sector intensifies, the industrial ecosystems and capital landscapes in which investment institutions operate are undergoing unprecedented reshaping.Against this backdrop, the "soft power" of investment institutions – ...

2026 - 09 - 04
Efung News | Trinomab’s Global First Anti-RSV Monoclonal Antibody Xinduotuo®, Offering One-Shot, 9-M

On September 3, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806, hereinafter referred to as "Trinomab") reached another significant milestone!Following the approval of Xintituo® (Generic Name: Stedostat Monoclonal Antibody Injection), the world's first innovative next-generation "tetanus shot," the company's independently developed global first recombinant anti-respiratory syncytial virus (RSV) fully human monoclonal antibody — Xinduotuo® (Generic Name: Ritevimab Monoclonal Antibody Injection, formerly known as TNM001 Injection) — has officially received marketing approval from the National Medical Products Administration (NMPA).Xinduotuo® is indicated for the prevention of lower respiratory tract infection caused by RSV in neonates and infants who are about to enter or were born in their first RSV season. With this approval, a new option is now available for passive immunity against RSV in all neonates and infants: as a ful...

2026 - 09 - 03
Efung Honor| The Power of Youth in Hard-Tech Arena! Effice Capital's CEO Zhu Pai Named to Qimingpia

Today, Qimingpian officially released its "2026 China U35 Outstanding Young Investors" list, and Mr. Zhu Pai, CEO of Effice Capital, has been honored on this prestigious roster.In 2026, the primary market is taking shape in a new landscape defined by "deep tech innovation, value consolidation, and industrial symbiosis." AI, humanoid robotics, semiconductors, commercial aerospace, healthcare, and hard tech have emerged as the market's core pillars. Technological moats, commercial viability, and long-term industrial value have become the industry's shared benchmarks.From the domestic breakthrough of high-end manufacturing and critical components, to the technological leap of generative AI and innovative biomedicine, and further to the refined operations and global expansion of emerging brands—every step forward in industry evolution is driven by the forward-looking strategies and professional partnership of investors and financial advisors. They irrigate the s...

2026 - 09 - 02
Efung Honor | Efung Capital Wins Dual Awards! Named to [Investors China] 2025-2026 Fund Partners Ran

Recently, Investors China released its prestigious 2025-2026 Fund Partners Ranking. Efung Capital has been honored as one of the Top 50 Best Venture Capital Institutions of 2025-2026, and our CEO, Mr. Zhu Pai, has been recognized among the Top 30 Best Venture Capital Investors of 2025-2026.Over the past year, China's equity investment industry has undergone a profound restructuring and value redefinition. The speculative logic that once profited from hot trends and quick flips is gradually losing its effectiveness. In its place emerges a new competitive landscape rooted in industrial fundamentals and long-term commitment—where the weak exit faster, and the strong ride the wave of change.This transformation is most vividly reflected in a "collective migration" across all investment stages—whether early-stage, growth-stage, mature-stage, or corporate venture capital—converging around the hard-tech theme. Early-stage investors remain committed to "investing ea...

2026 - 09 - 01

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务